Brain stimulation cut alcohol craving across 19 trials

Alcohol use disorder is defined largely by craving — the pull towards drinking that persists after the physical withdrawal has passed — and craving is one of the hardest targets to shift with existing treatments. Transcranial magnetic stimulation applies magnetic pulses through the scalp to modulate activity in specific brain regions, and has been trialled as a way to dampen that pull. Individual trials have been small and used very different settings, so it has been unclear whether the overall effect is real or whether particular protocols matter. Pooling the randomised evidence is the obvious next step towards more precise treatment strategies.

The authors ran a systematic review and meta-analysis, searching eight databases including PubMed, EMBASE, Cochrane Library, Web of Science and four Chinese-language databases up to 6 March 2026. They included randomised controlled trials comparing transcranial magnetic stimulation with sham stimulation in patients with alcohol use disorder, and assessed trial quality with the Cochrane Risk of Bias 2 tool. Outcomes were alcohol craving, abstinence days, alcohol intake, anxiety, depression and cognitive function. Nineteen randomised trials involving 942 patients were pooled using Stata15, with subgroup analyses by stimulation type, number of sessions, frequency and follow-up length, plus meta-regression to probe heterogeneity.

Compared with sham stimulation, transcranial magnetic stimulation significantly reduced alcohol craving. Subgroup analyses found significant effects where the stimulation type was continuous theta burst stimulation, where the number of sessions was 10 or 15, where the frequency was 10 Hz, and where follow-up was either up to 1 month or 3 months and beyond. Significant differences also emerged for maintaining abstinence days, reducing alcohol intake, easing depressive symptoms and improving cognitive function. Heterogeneity across trials was high, and meta-regression suggested disease type was the main contributor to it in the craving analysis. The authors flag that this uncertainty means the pooled estimates should be read cautiously.

This consolidates a scattered literature into a single direction of effect: across randomised comparisons, stimulation beats sham for craving rather than showing nothing. It extends the picture beyond craving to drinking behaviour, mood and cognition, which matters because those outcomes are what patients and clinicians actually care about. What it cannot do is tell you which protocol is best, since subgroup findings within a heterogeneous pool are hypothesis-generating rather than definitive. The authors are explicit that large-sample, multi-centre, double-blind randomised trials are still needed to confirm and refine these results.

This is a reason to think non-invasive brain stimulation is a genuine research avenue for alcohol use disorder rather than a fringe idea, and that its effects may extend to mood and thinking as well as craving. It is a clinical intervention delivered in a healthcare setting, not something anyone can arrange for themselves, and the pooled evidence is not strong enough to say who benefits most or which settings work best. For a general reader the useful takeaway is about the direction of travel in addiction treatment. Anyone affected by alcohol use disorder would be discussing options with a clinician rather than drawing conclusions from a heterogeneous pooled estimate.